红日药业：公司产品继续被纳入国家医保药品目录

Core Viewpoint - Hongri Pharmaceutical (300026) announced on December 8 that its product, Xuebijing Injection, will continue to be included in the new drug catalog for the years 2026 to 2027, following the renewal negotiations based on the recently published National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2025) by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [1] Group 1 - The company’s Xuebijing Injection will be renewed under the current conditions and included in the new drug catalog as a Class B drug [1]